Company Information

  

Address: 901 S. MOPAC EXPRESSWAY, STE. 250
BARTON OAKS PLAZA ONE 
City: AUSTIN 
State: TX 
Zip Code: 78746 
Telephone: (512) 942-2935 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer. Our engineered human enzymes are designed to degrade specific amino acids in the blood to target these diseases. In inborn errors of metabolism, or IEM, a subset of rare genetic diseases, we are seeking to reduce the toxic levels of amino acids in patients to the normal range. In oncology, we are seeking to reduce amino acid blood levels below the normal range where we believe we will be able to exploit the dependence of certain cancers on specific amino acids. Our lead product candidate, AEB1102 (pegzilarginase), is engineered to degrade the amino acid arginine and is being developed to treat two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers which have been shown to have a metabolic dependence on arginine.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
09/2017-1.75NAN/E
06/2017-1.55NAN/E
03/20174.41NA1.69
12/2016-2.22NAN/E
03/2016--NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.20Total Liab/Total Assets0.06
Net Inc/Total Assets-0.32Total Liab/Inv Cap0.06
Net Inc/Inv Cap-0.34Total Liab/Comm Equity0.04
Pretax Inc/Net Sales-4.69Interest Coverage RatioNA
Net Inc/Net Sales-4.69Curr Debt/EquityNA
Cash Flow/Net Sales-4.07LTD/EquityNA
SG&A/NetSales1.81Total Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables Turnover3.18Quick Ratio16.75
Inventory TurnoverNACurrent Ratio16.75
Inventory Day SalesNANet Rec/Curr Assets0.02
Net Sales/Work Cap0.07Inv/Curr AssetsNA
Net Sales/PP&E7.73  

Income Statement (Millions)

  9/30/2017 6/30/2017 3/31/2017 12/31/2016
Total Revenues(Net Sales) 1.26 1.48 0.98 1.25
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 3.02 2.37 2.36 2.05
Operating Income -8.00 -6.72 -6.33 -5.54
Interest Exp NA NA NA NA
Pretax Income -7.87 -6.63 -6.25 -5.48
Other Income 0.13 0.09 0.08 0.06
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -7.87 -6.63 -6.25 -5.48

Balance Sheet (Millions)

Assets 9/30/2017 6/30/2017 3/31/2017 12/31/2016
Cash & Short Term Investments 55.75 63.39 57.87 63.50
Receivables - Total 2.45 1.21 0.98 1.22
Inventories - Total NA NA NA NA
Total Current Assets 59.52 66.20 60.31 66.42
Net Property, Plant & Equipment 0.84 0.80 0.82 0.60
Total Assets 60.50 67.14 61.27 67.06
Liabilities        
Accounts Payable 4.83 4.35 3.91 3.89
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 4.88 4.42 3.96 3.97
Long-Term Debt NA NA NA NA
Total Liabilities 4.99 4.54 4.08 4.10
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.00 0.00 0.00 0.00
Retained Earnings -66.03 -58.16 -51.52 -45.28
Treasury Stock NA NA NA NA
Total Stockholders' Equity 55.51 62.60 57.18 62.97
Total Liabilities and Stockholders' Equity 60.50 67.14 61.27 67.06

Cash Flow Summary (Millions)

Categories 9/30/2017 6/30/2017 3/31/2017 12/31/2016
Net Cash Provided by Operating Activities -7.37 -5.94 -5.43 -4.36
Net Cash Provided by Investing Activities -6.29 4.52 -25.61 2.56
Net Cash Provided by Financing Activities -0.12 11.55 0.10 0.00

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20140.00-10.35--
12/20156.08-11.30--
12/20164.63-21.70-2.22
Growth RatesInfinity----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/17407,87147.29




Report Date : 12/11/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.